Dysregulated hematopoiesiscausedbymammary Cancer is associated with epigenetic changes and Hox gene expression in hematopoietic cells

Cancer Research

Volumn 73, Issue 19, 2013, Pages 5892-5904

  Sio, Alexander ^a   Chehal, Manreet K ^a   Tsai, Kevin ^a   Fan, Xueling ^a   Roberts, Morgan E ^a   Nelson, Brad H ^b   Grembecka, Jolanta ^c   Cierpicki, Tomasz ^c   Krebs, Danielle L ^a   Harder, Kenneth W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; POLYCOMB REPRESSIVE COMPLEX 2; STEM CELL FACTOR RECEPTOR; FLT3 LIGAND PROTEIN; HISTONE; MEMBRANE PROTEIN; MESSENGER RNA;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELLULAR DISTRIBUTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCATION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HISTONE METHYLATION; HOX GENE; IN VITRO STUDY; LEUKEMOID REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BONE MARROW; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYTOLOGY; DNA METHYLATION; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; FLOW CYTOMETRY; GENETICS; HOMEOBOX; LEUKOCYTOSIS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; COMPLICATION;

ANEMIA; ANIMALS; BLOTTING, WESTERN; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; EPIGENOMICS; FEMALE; FLOW CYTOMETRY; GENES, HOMEOBOX; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HISTONES; LEUKOCYTOSIS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84885065133     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0842     Document Type: Article

References (50)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
2. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
3. Wilcox RA. Cancer-associated myeloproliferation: old association, new therapeutic target. Mayo Clin Proc 2010;85:656-63.
4. Qiu MZ, Xu RH, Ruan DY, Li ZH, Luo HY, Teng KY, et al. Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China. Tumour Biol 2010;31:633-41.
5. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011;29:610-8.
6. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008;205:2125-38.
7. Cedar H, Bergman Y. Epigenetics of haematopoietic cell development. Nat Rev Immunol 2011;11:478-88.
8. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-6.
9. Mills AA. Throwing the cancer switch: reciprocal roles of Polycomb and Trithorax proteins. Nat Rev Cancer 2010;10:669-82.
10. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43.
11. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004;15:57-67.
12. Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, Weersing E, et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 2006;107:2170-9.
13. Majewski IJ, Blewitt ME, de Graaf CA, McManus EJ, Bahlo M, Hilton AA, et al. Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol 2008;6:e93.
14. van Oostveen J, Bijl J, Raaphorst F, Walboomers J, Meijer C. The role of homeobox genes in normal hematopoiesis and hematological malignancies. Leukemia 1999;13:1675-90.
15. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of Polycomb-mediated gene silencing. Cell 2007;130:1083-94.
16. Bach C, Buhl S, Mueller D, Garcia-Cuellar MP, Maethner E, Slany RK. Leukemogenic transformation by HOXA cluster genes. Blood 2010;115:2910-8.
17. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
18. Wall EM, Milne K, Martin ML, Watson PH, Theiss P, Nelson BH. Spontaneousmammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Re 2007;67:6442-50.
19. + T cells lacking the Cbl-β gene. Cancer Immunol Immunother 2009;58:1865-75.
20. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a (-/-) 5b (-/-) mice due to decreased survival of early erythroblasts. Blood 2001;98:3261-73.
21. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961;14:213-22.
22. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011;121:784-99.
23. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007;9:212.
24. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011;121:3804-9.
25. + myeloid cells. Nat Biotechnol 2007;25:911-20.
26. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007;26:6766-76.
27. He H, Hua X, Yan J. Epigenetic regulations in hematopoietic Hox code. Oncogene 2011;30:379-88.
28. Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 2010;17:148-59.
29. Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H, et al. Haematopoietic malignancies caused by dysregulation of a chromatinbinding PHD finger. Nature 2009;459:847-51.
30. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012;8:277-84.
31. Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, Silva A, et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci U S A 2006;103:1018-23.
32. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012;21:836-47.
33. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
34. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFN-a activates dormant haematopoietic stem cells in vivo. Nature 2009;458:904-8.
35. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-g in response to chronic infection. Nature 2010;465:793-7.
36. de Haan G, Loeffler M, Nijhof W. Long-term recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment severely depresses murine marrow erythropoiesis without causing an anemia. Exp Hematol 1992;20:600-4.
37. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A 2012;109:2491-6.
38. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21.
39. DuPre SA, Hunter KW Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumorderived growth factors. Exp Mol Pathol 2007;82:12-24.
40. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloidderived suppressor cell-dependent mechanism. PLoS One 2011;6:e27690.
41. Brasel K, McKenna HJ, Charrier K, Morrissey PJ, Williams DE, Lyman SD. Flt3 ligand synergizeswith granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 1997;90:3781-8.
42. Asano T, Morimoto S, Kitami Y, Miyauchi T, Sakai K, Takagi K. [Bladder cancer producing granulocyte colony-stimulating factor (G-CSF): a case report]. Hinyokika Kiyo 2002;48:495-8.
43. Yoshino T, Yoneda K. [Urinary bladder cancer producing granulocytecolony stimulating factor: a case report and review of the literature]. Hinyokika Kiyo 2008;54:775-8.
44. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007;9:R15.
45. Park S, Kim ES, Noh DY, Hwang KT, Moon A. H-Ras-specific upregulation of granulocyte colony-stimulating factor promotes human breast cell invasion via matrix metalloproteinase-2. Cytokine 2011;55:126-33.
46. Lawicki S, Czygier M, Omyla J, Bedkowska E, Szmitkowski M. [The plasma levels of granulocyte-colony stimulating factor and granulocytemacrophage colony stimulating factor in breast cancer patients]. Pol Merkur Lekarski 2007;23:259-63.
47. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, et al. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep 2007;17:687-94.
48. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008;133:994-1005.
49. Matsumoto Y, Mabuchi S, Muraji M, Morii E, Kimura T. Squamous cell carcinoma of the uterine cervix producing granulocyte colony-stimulating factor: a report of 4 cases and a review of the literature. Int J Gynecol Cancer 2010;20:417-21.
50. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, et al. Overexpression of themyeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 2002;99:121-9.